The OCEANIC-AF trial has raised concerns about factor XI inhibitors. Should physicians still bet on this class of ...

There are plenty of great investment alternatives in the healthcare sector. You won't need a boatload of money to get started, either. Here are two no-brainer healthcare stocks to buy with $500 right ...

New Delhi: Pfizer Ltd on Friday said its board has approved signing a marketing and supply agreement with Mylan ...

Pfizer has announced that it has entered into a marketing and supply agreement with Mylan Pharmaceuticals for the marketing and sale of two of its brands, Ativan and Pacitane.

Mylan, which has an established presence in the central nervous system therapy segment, is expected to leverage its network ...

Greek-American Pfizer CEO Dr Albert Bourla faced an unwelcoming reception at the White House during an event celebrating ...

The CEO of Pfizer received loud boos when he was introduced by Donald Trump at a Black History Month event at the White House ...

President Donald Trump's introduction of a Pfizer executive at the White House Wednesday was met with a roar of boos from the crowd.

Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...

Pfizer (NYSE:PFE) has decided to end R&D and marketing activities related to Beqvez, a one-time gene therapy the company has ...

An intriguing battle is brewing in the market to treat patients with transthyretin amyloid cardiomyopathy (ATTR-CM). | BridgeBio reported that 1,028 unique prescriptions have been written by 516 ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...